TAP1 and urinary bladder cancer: Further, data on cancer therapeutic responses to immune therapy indicated that cohorts with melanoma or bladder cancer and high TAP1 expression had a greater proportion of responders, indicating that patients with melanoma and bladder cancer and high TAP1 levels had both worse clinical prognosis and were potentially more sensitive to ICI therapy.